The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Dietary l -Arginine Reduces the Progression of Atherosclerosis in Cholesterol-Fed Rabbits: Comparison With Lovastatin
Abstract
Background We investigated whether l -arginine induces regression of preexisting atheromatous lesions and reversal of endothelial dysfunction in hypercholesterolemic rabbits, whether similar effects can be obtained by cholesterol-lowering therapy with lovastatin, and which mechanism leads to these effects. Methods and Results Rabbits were fed 1% cholesterol for 4 weeks and 0.5% cholesterol for an additional 12 weeks. Two groups of cholesterol-fed rabbits were treated with l -arginine (2.0% in drinking water) or lovastatin (10 mg/d) during weeks 5 through 16. Systemic nitric oxide (NO) formation was assessed as the urinary excretion rates of nitrate and cGMP in weekly intervals. Cholesterol feeding progressively reduced urinary nitrate excretion to ≈40% of baseline ( P <.05) and increased plasma concentrations of asymmetrical dimethylarginine (ADMA), an endogenous NO synthesis inhibitor. Dietary l -arginine reversed the reduction in plasma l -arginine/ADMA ratio and partly restored urinary excretion of nitrate and cGMP (each P <.05 vs cholesterol) but did not change plasma cholesterol levels. l -Arginine completely blocked the progression of carotid intimal plaques, reduced aortic intimal thickening, and preserved endothelium-dependent vasodilator function. Lovastatin treatment reduced plasma cholesterol by 32% but did not improve urinary nitrate or cGMP excretion or endothelium-dependent vasodilation. Lovastatin had a weaker inhibitory effect on carotid plaque formation and aortic intimal thickening than l -arginine. l -Arginine inhibited but lovastatin potentiated superoxide radical generation in the atherosclerotic vascular wall. Conclusions Dietary l -arginine improves NO-dependent vasodilator function in cholesterol-fed rabbits and completely blocks the progression of plaques via restoration of NO synthase substrate availability and reduction of vascular oxidative stress. Lovastatin treatment has a weaker inhibitory effect on the progression of atherosclerosis and no effect on vascular NO elaboration, which may be due to its stimulatory effect on vascular superoxide radical generation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Hypercholesterolemia increases endothelial superoxide anion production.
Ohara, Y., Peterson, T. E., & Harrison, D. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116491 · Cited by 1,765
Cited by
Arginine metabolism and nutrition in growth, health and disease
Wu, G., Bazer, F. W., Davis, T. A., Kim, S. W., Li, P., Marc Rhoads, J., Carey Satterfield, M., Smith, S. B., Spencer, T. E., & Yin, Y. (2009) · Amino Acids · doi:10.1007/s00726-008-0210-y · Cited by 1,362
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Endogenous Nitric Oxide Synthase Inhibitor: A Novel Marker of Atherosclerosis
Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S., Okuda, S., & Imaizumi, T. (1999) · Circulation · doi:10.1161/01.cir.99.9.1141 · Cited by 756
Does ADMA Cause Endothelial Dysfunction?
Cooke, J. P. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.9.2032 · Cited by 581
Böger, R. H., Sydow, K., Borlak, J., Thum, T., Lenzen, H., Schubert, B., Tsikas, D., & Bode-Böger, S. M. (2000) · Circulation Research · doi:10.1161/01.res.87.2.99 · Cited by 479
Self-citationBiological significance of endogenous methylarginines that inhibit nitric oxide synthases
Leiper, J. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00162-5 · Cited by 458
Sydow, K., & Münzel, T. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00033-3 · Cited by 433
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
BOGER, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00500-5 · Cited by 393
Self-citationBöger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Self-citationKIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103594 · Cited by 361
The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio
BODEBOGER, S., SCALERA, F., & IGNARRO, L. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.002 · Cited by 347
The Clinical Pharmacology of L-Arginine
Böger, R. H., & Bode-Böger, S. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.79 · Cited by 331
Zoccali, C., Benedetto, F. A., Maas, R., Mallamaci, F., Tripepi, G., Salvatore Malatino, L., & Bo[Combining Diaeresis]ger, R. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132490 · Cited by 319
Ozaki, M., Kawashima, S., Yamashita, T., Hirase, T., Namiki, M., Inoue, N., Hirata, K.-I., Yasui, H., Sakurai, H., Yoshida, Y., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15215 · Cited by 312
Böger, R. H., Bode-Böger, S. M., Sydow, K., Heistad, D. D., & Lentz, S. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1557 · Cited by 278
Self-citationRaitakari, O. T., & Celermajer, D. S. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00277.x · Cited by 272
Ozaki, M., Kawashima, S., Yamashita, T., Hirase, T., Namiki, M., Inoue, N., Hirata, K.-I., Yasui, H., Sakurai, H., Yoshida, Y., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215215 · Cited by 268
Böger, R. H., Bode-Böger, S. M., Thiele, W., Creutzig, A., Alexander, K., & Frölich, J. C. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00375-1 · Cited by 264
The role of asymmetric and symmetric dimethylarginines in renal disease
Schwedhelm, E., & Böger, R. H. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.31 · Cited by 260
Kapil, V., Khambata, R. S., Jones, D. A., Rathod, K., Primus, C., Massimo, G., Fukuto, J. M., & Ahluwalia, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019240 · Cited by 248
Fujiwara, N., Osanai, T., Kamada, T., Katoh, T., Takahashi, K., & Okumura, K. (2000) · Circulation · doi:10.1161/01.cir.101.8.856 · Cited by 242
Endothelial nitric oxide (NO) and its pathophysiologic regulation
Chatterjee, A., & Catravas, J. D. (2008) · Vascular Pharmacology · doi:10.1016/j.vph.2008.06.008 · Cited by 236
“Administration of l-arginine (Aji et al., 1997; Boger et al., 1997) or tetrahydrobiopterin (Hattori et al.”
BackgroundN., C., & J., C. (2002) · Diabetologia · doi:10.1007/s00125-002-0975-6 · Cited by 116
Cardioprotective effect of tender coconut water in experimental myocardial infarction
Anurag, P., & Rajamohan, T. (2003) · Plant Foods for Human Nutrition · doi:10.1023/b:qual.0000040363.64356.05 · Cited by 75
Metadata
- Authors
- Böger, R. H., Bode-Böger, S. M., Brandes, R. P., Phivthong-ngam, L., Böhme, M., Nafe, R., Mügge, A., & Frölich, J. C.
- Venue
- Circulation
- Published
- 1997-08-19
- Volume
- 96
- Issue
- 4
- Pages
- 1282-1290
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2054949240
- Cited by
- 242
- References
- 2
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.